Health care industry
Neuralink rival Synchron lets patients control Apple Vision Pro with their thoughts
Mark uses the Vision Pro with his BCI Courtesy of Synchron Neurotech startup Synchron on Tuesday announced it has connected its brain implant to Apple‘s Vision Pro headset. It’s now possible for patients with limited physical mobility to control the device using only their thoughts. Synchron is building a brain-computer interface, or a BCI, designed […]
Read More
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology […]
Read More
We’re encouraged by Abbott stock trading but discouraged by moves in Honeywell
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market moves: The S & P 500 was on track for small gains following a solid rally last Friday. There’s still some market rotation happening, but […]
Read More
Here are JPMorgan’s top drug stock picks into earnings
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of 2024 have shifted and sparked a rotation out of large technology stocks into less-loved areas of the market, including value stocks and small caps. The […]
Read More
Jim Cramer’s advice on Abbott Labs stock after a nearly $500 million baby formula verdict
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Wall Street was lower after Friday’s rebound in a wild week that featured rotations in and out of tech. It’s a busy week ahead with a Fed meeting, 14 earnings […]
Read More
We’re making a flurry of moves: trimming 2 stocks and buying 2 others that have lagged
We’re making four trades Monday morning. Shortly after the opening bell, we will be selling 100 shares of Danaher at roughly $274.13. Following the trade, Jim Cramer’s Charitable Trust will own 475 shares of Danaher, decreasing its weighting in the portfolio to 4% from 4.84%. In addition, we will be selling 20 shares of Salesforce at […]
Read More
FDA approves new blood test to screen for colon cancer
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield […]
Read More
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at stake, that’s pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. But the reality of the coming competition has grown more tangible after recent announcements from rival drugmakers Roche and […]
Read More
Dexcom shares plunge more than 40%, head for worst day on record
Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop […]
Read More
An ugly earnings report from a competitor is good news for Abbott Labs
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Stocks jumped Friday as Wall Street tried to end a turbulent week on a jubilant note. The Dow Jones Industrial Average added more more than 600 points, or 1.6%. The […]
Read More